Comparison of kidney and hepatic outcomes among sodium-glucose cotransporter-2 inhibitors: a retrospective study using multiple propensity scores.
鈉-葡萄糖共轉運蛋白-2 抑制劑在腎臟和肝臟結果的比較:使用多重傾向評分的回顧性研究。
J Pharm Health Care Sci 2024-09-16
Comparison of cardiovascular and renal outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes without prior cardiovascular or renal disease.
二型糖尿病患者中,無心血管或腎臟疾病病史的患者,達帕格列酮和恩帕格列酮在心血管和腎臟結果之比較。
PLoS One 2022-12-07
Long-Term, Real-World Kidney Outcomes with SGLT2i versus DPP4i in Type 2 Diabetes without Cardiovascular or Kidney Disease.
第二型糖尿病患者中長期實際世界中SGLT2i與DPP4i對腎臟結果的比較,而無心血管或腎臟疾病。
Clin J Am Soc Nephrol 2023-10-12
Differential effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes according to renal function: a dose-response meta-analysis involving 10 randomized clinical trials and 71 553 individuals.
腎功能不同對鈉葡萄糖共轉運蛋白2抑制劑在心血管和腎臟結果上的差異影響:涉及10個隨機臨床試驗和71,553名個體的劑量反應荟萃分析。
Eur J Endocrinol 2023-08-04
Sodium-glucose co-transporter-2 inhibitors are associated with kidney benefits at all degrees of albuminuria: A retrospective cohort study of adults with diabetes.
葡萄糖鈉共同轉運蛋白2抑制劑與腎臟益處相關聯:對糖尿病成年人進行的一項回顧性cohort研究。
Diabetes Obes Metab 2024-01-11
Comparison of Effectiveness Among Different Sodium-Glucose Cotransoporter-2 Inhibitors According to Underlying Conditions: A Network Meta-Analysis of Randomized Controlled Trials.
不同基礎疾病患者間不同鈉葡萄糖共同轉運蛋白2抑制劑的效果比較:隨機對照試驗的網絡Meta分析。
J Am Heart Assoc 2024-03-12
Comparison of estimated glomerular filtration rate change with sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists among people with diabetes: A propensity-score matching study.
糖尿病患者中使用鈉葡萄糖共同轉運蛋白-2抑制劑與胰高血糖素樣肽-1受體激動劑對估計腎小球過濾率變化的比較:一項傾向性配對研究。
Diabetes Obes Metab 2024-03-26
Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Type 2 Diabetes.
SGLT2 抑制劑與 GLP-1 受體激動劑在 2 型糖尿病中的腎臟與心血管效果比較。
J Am Coll Cardiol 2024-08-14
Comparative renal outcomes of matched cohorts of patients with type 2 diabetes receiving SGLT2 inhibitors or GLP-1 receptor agonists under routine care.
接受常規護理的2型糖尿病患者中,使用SGLT2抑制劑或GLP-1受體激動劑的匹配隊列比較腎臟結果。
Diabetologia 2024-08-23
Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Kidney Outcomes across Baseline Cardiovascular-Kidney-Metabolic Conditions: A Systematic Review and Meta-Analyses.
鈉-葡萄糖共轉運蛋白-2 抑制劑對基線心血管-腎臟-代謝狀況下腎臟結果的影響:系統性回顧與統合分析。
J Am Soc Nephrol 2024-09-04
Risk of hepatic events associated with use of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists, and thiazolidinediones among patients with metabolic dysfunction-associated steatotic liver disease.
與使用鈉-葡萄糖共轉運蛋白-2抑制劑相比,使用胰高血糖素樣肽-1受體激動劑和噻唑烷二酮在代謝功能障礙相關脂肪肝疾病患者中肝臟事件的風險。
Gut 2024-09-06